Results 121 to 130 of about 4,852 (207)

Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort. [PDF]

Viruses, 2023
Lazzaro A, Bianchini D, Gentilini Cacciola E, Mezzaroma I, Falciano M, Andreoni C, Fimiani C, Santinelli L, Maddaloni L, Bugani G, Ceccarelli G, Mastroianni CM, d'Ettorre G.   +12 more
europepmc   +1 more source

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

, 2019
Joseph J. Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank A. Post, Christoph Stephan, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Romana Petrovic, Kimberley Brown, Erika Van Landuyt, Magda Opsomer, Christoph Stephan, Éric Florence, Michel Moutschen, Eric Van Wijngaerden, Linos Vandekerckhove, Bernard E. Van Beers, Jason Brunetta, Brian Conway, Marina B. Klein, Daniel Murphy, Anita Rachlis, Stephen D. Shafran, Sharon Walmsley, F. Ajana, Laurent Cotte, P.-M. Girardy, Christine Katlama, Jean‐Michel Molina, Isabelle Poizot‐Martin, François Raffi, D. Rey, Jacques Reynes, Elina Teicher, Yazdan Yazdanpanah, Jacek Gąsiorowski, Waldemar Halota, Andrzéj Horban, Anna Piekarska, Anita Witor, José Ramón Arribas, Ignacio Valero, Juan Berenguer, José L. Casado, José M. Gatell, Félix Gutiérrez, Marı́a José Galindo, María del Mar Gutiérrez, José Antonio Iribarren, Hernando Knobel, Eugènia Negredo, Juan A. Pineda, Daniel Podzamczer, Joaquín Portilla, Federico Pulido, C Ricart, Antonio Rivero, I Santos Gil, Anders Blaxhult, Leo Flamholc, Magnus Gisslén, Anders Thalme, Jan Fehr, Andri Rauch, Marcel Stoeckle, Amanda Clarke, B Gazzard, Mikayla Johnson, Chloe Orkin, Frank A. Post, Andrew Ustianowski, Laura Waters, Joseph I. Bailey, Paul Benson, Laveeza Bhatti, Indira Brar, U. Fritz Bredeek, Cynthia Brinson, Gordon Crofoot, Douglas Cunningham, E DeJesus, Craig Dietz, Robin Dretler, Joseph J. Eron, Franco Felizarta, Carl J. Fichtenbaum, Joel E. Gallant, Joseph Gathe, Debbie Hagins, S Henn, W. Keith Henry, Gregory Huhn, Mamta K. Jain, Christopher Lucasti, Claudia Martorell, Cheryl McDonald, Anthony Mills, Javier O Morales-Ramirez   +99 more
openalex   +1 more source

IDDF2020-ABS-0060 Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF [PDF]

, 2020
Henry Lik‐Yuen Chan, Pietro Lampertico, Sang Hoon Ahn, Scott Fung, Ho Bae, Alnoor Ramji, Jung Sung Lee, Stephen Shafran, Stuart C. Gordon, Charles Phan, Susanna K. Tan, John F. Flaherty, Anuj Gaggar, George Y. Wu, Vithika Suri, Daryl Lau, Kwan Soo Byun, Kosh Agarwal, Young‐Suk Lim, Marı́a Buti   +19 more
openalex   +1 more source

Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B. [PDF]

Exp Ther Med, 2021
Chen P, Wei W, Jin L, Kuai W, Li F, Liu H, Jiang B, Zhu Y.   +7 more
europepmc   +1 more source

Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Hu X, Kong Y, Liu Y, Liu T, Ma A, Li Y, Zhang Y, Li J, Zhang L, Li G.   +9 more
europepmc   +1 more source

P030: Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate

Journal of the International AIDS Society, 2015
Edwin DeJesus, Paul Sax, Michael Yin, Frank Post, Shinichi Oka, Ellen Koenig, Benoit Trottier, Jaime Andrade-Villanueva, Huyen Cao, Julie Ryu, Marshall Fordyce   +10 more
openaire   +1 more source

Deep sequencing analysis of hepatitis B virus in patients with incomplete response to tenofovir alafenamide fumarate treatment. [PDF]

World J Hepatol
Yamada N, Igarashi H, Murayama A, Suzuki M, Yasuda K, Saito M, Isogawa M, Kato T.   +7 more
europepmc   +1 more source

Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins.

JAMA Netw Open, 2023
Rivera AS, Pak KJ, Mefford MT, Hechter RC.   +3 more
europepmc   +1 more source

Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques. [PDF]

EBioMedicine, 2022
Dobard CW, Peet MM, Nishiura K, Holder A, Dinh C, Mitchell J, Khalil G, Pan Y, Singh ON, McCormick TJ, Agrahari V, Gupta P, Jonnalagadda S, Heneine W, Clark MR, García-Lerma JG, Doncel GF.   +16 more
europepmc   +1 more source

Long-term metabolic and safety profiles of tenofovir alafenamide and tenofovir disoproxil fumarate in ART-naive people living with HIV: a multicenter retrospective study using a mixed-effects model [PDF]

Oğuz Karabay, Aslı Vatan, Abdullah Uçar, Ilknur Yilmaz, N Baltä, Arzu Kantürk, Rıdvan Dumlu, Yasemin Çağ, Hülya Çaşkurlu, Merve Tokgöz Şık, Zahide Aşık Otman, Umay Balcı, Seniha Şenbayrak, Sıla Akhan, Müge Toygar Deniz, Dilek YEKENKURUL, Nevin İnce, Bekir TUNCA, Tuba Damar Çakırca, Aliye Baştuğ, Ünal Erkorkmaz, Ertuğrul Güçlü   +21 more
openalex   +1 more source